Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

GeneDx Holdings (WGS) EBIAT (2020 - 2025)

GeneDx Holdings (WGS) has disclosed EBIAT for 6 consecutive years, with -$17.7 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIAT fell 424.86% to -$17.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$21.0 million, a 59.8% increase, with the full-year FY2025 number at -$21.0 million, up 59.8% from a year prior.
  • EBIAT was -$17.7 million for Q4 2025 at GeneDx Holdings, down from -$7.6 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $32.7 million in Q3 2021 to a low of -$308.8 million in Q4 2022.
  • A 5-year average of -$52.2 million and a median of -$34.8 million in 2021 define the central range for EBIAT.
  • Peak YoY movement for EBIAT: skyrocketed 157.81% in 2021, then tumbled 663.75% in 2022.
  • GeneDx Holdings' EBIAT stood at -$40.4 million in 2021, then crashed by 663.75% to -$308.8 million in 2022, then surged by 91.65% to -$25.8 million in 2023, then soared by 121.1% to $5.4 million in 2024, then tumbled by 424.86% to -$17.7 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's EBIAT are -$17.7 million (Q4 2025), -$7.6 million (Q3 2025), and $10.8 million (Q2 2025).